All In Biotech

Drug Trial Radar · NCT07238868

An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of CB03-154 in Subjects Diagnosed With Epilepsy

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Aug 14, 2025

Primary completion

Jan 2029

Study completion Jun 2029

Sponsor

Sponsor type
Industry
First posted
Nov 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Conditions

  • Focal Epilepsy

Interventions

  • CB03-154Drug

    All enrolled subjects will begin with a two-week course of CB03-154 at 10 mg QD. Upon demonstrating good tolerability, the dose will be increased to 20 mg QD and continued for up to two years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the long-term tolerability and safety of CB03-154 in patients diagnosed with epilepsy.Time frame: In the entire period of the whole study, including a treatment period up to 2 years (104 weeks) and a post treatment follow-up period of 8 weeks.
  2. To assess the long-term efficacy of CB03-154 in patients diagnosed with epilepsy.Time frame: In the entire period of the whole study, including a treatment period up to 2 years (104 weeks) and a post treatment follow-up period of 8 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alfred Health

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.